Biblio
Export 751 results:
Author [ Title] Type Year Filters: First Letter Of Keyword is P [Clear All Filters]
“An Alternative View of Familial Alzheimer's Disease Genetics.”, J Alzheimers Dis, vol. 96, no. 1, pp. 13-39, 2023.
, “Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.”, J Alzheimers Dis, vol. 61, no. 2, pp. 631-644, 2018.
, “Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development.”, J Alzheimers Dis, vol. 91, no. 1, pp. 43-70, 2023.
, “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.”, Neuron, vol. 78, no. 4, pp. 631-43, 2013.
, “Alzheimer's Disease rs11767557 Variant Regulates EPHA1 Gene Expression Specifically in Human Whole Blood.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1077-1088, 2018.
, “Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.”, J Alzheimers Dis, vol. 57, no. 3, pp. 765-773, 2017.
, “Analysis and Identification Genetic Effect of SARS-CoV-2 Infections to Alzheimer's Disease Patients by Integrated Bioinformatics.”, J Alzheimers Dis, vol. 85, no. 2, pp. 729-744, 2022.
, “Anemia and Mild Cognitive Impairment in the German General Population.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1031-42, 2016.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
, “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
, “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
, “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
, “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
, “Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1085-97, 2016.
, “Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1085-97, 2016.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Apathy and Attentional Biases in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 837-46, 2016.
, “Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 705-715, 2018.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
,